Recombinant peptide vaccine (National Cancer Institute)
N/A
Report date: 2022/01/14 13:23:58
Base Information
Drug NameRecombinant peptide vaccine (National Cancer Institute)
Drug Alias NameN/A
Classification
Mechanisms of Action
Targets
Therapy Area/Indications
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsNo
Global Highest StatusPending (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesNational Cancer Institute
China Registration ClassN/A
Develop Information
Active CompaniesN/A
Inactive CompaniesNational Cancer Institute
Active IndicationsN/A
Inactive Indications
Other Information
ATC CodeN/A
Related LinksN/A